Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia
Caroline Dafflon(Novartis (Switzerland)), Ralph Tiedt(Novartis (Switzerland)), Barbara Schacher Engstler(Novartis (Switzerland)), Juerg Schwaller(University Hospital of Basel), Hélène Méreau(University Hospital of Basel), Vanessa J. Craig(University of Zurich), Julius Gräsel(Novartis (Switzerland)), William R. Sellers(Broad Institute), Florian Nigsch(Novartis (Switzerland)), C Stork-Fux(Novartis (Switzerland)), Greg Hoffman(Novartis (United States)), Amelie Proske(Novartis (Switzerland)), Júlia Aguadé-Gorgorió(University of California, Los Angeles), Louise Barys(Novartis (Switzerland)), Masato Murakami(Novartis (Switzerland)), F. Hofmann(Novartis (Switzerland)), Beat Bornhäuser(University Children's Hospital Zurich), Moriko Ito(Novartis (Switzerland)), Swann Gaulis(Novartis (Switzerland))
Cited by 114
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Gene expression correlates of clinical prostate cancer behavior
|Cancer Cell|2002|2.5k